Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGNX vs BMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGNX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–2 Matrix Metrics)

CGNX Overall Winner 6-Pillar Tally: CGNX 6 – 0 BMI Matrix Metrics: CGNX 7 – 2 BMI

As of Nov 16, 2026, Cognex Corp (CGNX) is the stronger overall head-to-head candidate over Badger Meter, Inc. (BMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGNX carries a Unified Composite Score of 59.5/100 (HOLD) at $48.06 (24.7x Forward P/E, 25.0% operating margin), whereas BMI carries 46.0/100 (HOLD) at $160.76 (31.0x Forward P/E, 18.8% operating margin).

  • Technical & Structure Timing Caution: CGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.9); meanwhile BMI trades in a Markup technical trend (SURGE options phase, RSI 62.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGNX vs BMI
CGNX NASDAQ Head-to-Head Winner
Cognex Corp
Industrial Instruments For Measurement, Display, And Control
$48.06
-3.9% 1D
Market Cap $8.5B
TTM Revenue $1.13B
Forward P/E 24.7x
Beta / 30D Vol 2.19β · 65% Vol
Unified Composite Score
59.5 / 100 HOLD
Tech 45.0 Fund 54.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.1%), weak momentum, RSI 36
RSI-14: 35.9 · SMA20: $53.86 · SMA50: $57.80
BMI NYSE
Badger Meter, Inc.
Totalizing Fluid Meters & Counting Devices
$160.76
+3.9% 1D
Market Cap $4.5B
TTM Revenue $881M
Forward P/E 31.0x
Beta / 30D Vol 0.49β · 67% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 32.0 Fund 47.0 Flow 56.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 62
RSI-14: 62.0 · SMA20: $152.37 · SMA50: $137.75

6-Pillar Scorecard Institutional Category Breakdown (CGNX 6 – 0 BMI)

Columns: Metric · CGNX · BMI
1. Valuation Multiples CGNX
Forward P/E 24.7x 31.0x
Trailing P/E 35.5x 35.5x
PEG Ratio 2.71x 3.68x
EV / Revenue 7.0x 5.1x
2. Growth & Scale CGNX
Revenue Growth (YoY) +13.2% +0.1%
Earnings Growth (YoY) +400.0% +4.2%
TTM Revenue (USD) $1.13B $881M
Market Cap $8.5B $4.5B
3. Profitability & Quality CGNX
Gross Margin 69.7% 41.6%
Operating Margin 25.0% 18.8%
Net Profit Margin 21.5% 14.4%
Return on Equity (ROE) 15.1% 18.7%
4. Balance Sheet & Cash Flow CGNX
Cash Generation (TTM) $286M $142M
Cash Flow Margin 25.4% 16.2%
Net Cash / Leverage $624M Net Cash $22.80 Book/Sh · 18.7% ROE
Dividend Yield 0.66% 1.03%
5. Options & Positioning CGNX
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 53.5% (16th %ile) 39.0% (7th %ile)
Put/Call OI Skew 1.96x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat CGNX
OpEx & R&D Intensity 44.7% of Rev ($503M) 22.8% of Rev ($201M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Scientific & Technical Instruments Operator Scientific & Technical Instruments Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGNX (7) vs BMI (2)
Institutional Metric CGNX BMI Criterion Row Edge
Market Capitalization
Scale
$8.5B $4.5B Larger Scale CGNX
Trailing P/E Ratio
Valuation
35.5x 35.5x Lower Multiple Tie
Forward P/E Ratio
Valuation
24.7x 31.0x Lower Multiple CGNX
Revenue Growth (YoY)
Growth
+13.2% +0.1% Higher Growth CGNX
Operating Margin (TTM)
Profitability
25.0% 18.8% Higher Margin CGNX
Net Profit Margin
Profitability
21.5% 14.4% Higher Margin CGNX
Return on Equity (ROE)
Capital Efficiency
15.1% 18.7% Higher ROE BMI
52-Week Range Position
Momentum
35% ($35–$73) 65% ($112–$187) Stronger Trend BMI
Beta / 30D Volatility
Risk Regime
2.19β · 65% Vol 0.49β · 67% Vol Lower Realized Risk CGNX
Unified Institutional Score
Composite Signal
59.5 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite CGNX
Trailing 12M Revenue (USD)
Operating Scale
$1.13B $881M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
69.7% 41.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.71x PEG · 7.0x EV/Rev 3.68x PEG · 5.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$286M ($624M Net Cash) $142M ($22.80 Book/Sh · 18.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMI +38.08 pp
CGNX: -10.98% · BMI: +27.1%
3M Horizon BMI +51.91 pp
CGNX: -24.21% · BMI: +27.7%
6M Horizon BMI +57.51 pp
CGNX: -22.37% · BMI: +35.14%
1Y Horizon CGNX +39.3 pp
CGNX: +29.72% · BMI: -9.58%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGNX Revenue BMI Revenue CGNX Op. Margin BMI Op. Margin Margin Leader
FY2018 $810M $430M 27.4% 13.1% CGNX
FY2019 $730M $420M 19.7% 14.6% CGNX
FY2020 $810M $430M 21.0% 15.3% CGNX
FY2021 $1.04B $510M 30.4% 15.6% CGNX
FY2022 $1.01B $570M 24.5% 15.4% CGNX
FY2023 $840M $700M 15.6% 16.8% BMI
FY2024 $910M $830M 12.6% 19.1% BMI
FY2025 $990M $920M 16.3% 20.0% BMI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGNX BREAKDOWN
120d in phase · OBV ACCUMULATION
Current IV 53.5%
IV Percentile 16th %ile
Put/Call OI Skew 1.96x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMI SURGE
7d in phase · OBV NEUTRAL
Current IV 39.0%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGNX Moat Profile Scale & Operating Efficiency Moat
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $8.5B market capitalization and 25.0% operating margin.
OpEx & R&D Reinvestment 44.7% of Rev ($503M)
90D Engineering Disclosures 0 Published
BMI Moat Profile Scale & Operating Efficiency Moat
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $4.5B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment 22.8% of Rev ($201M)
90D Engineering Disclosures 0 Published

Investor FAQ CGNX vs BMI Key Questions & Quantitative Answers

As of Nov 16, 2026, Cognex Corp (CGNX) is the stronger overall head-to-head candidate over Badger Meter, Inc. (BMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGNX carries a Unified Composite Score of 59.5/100 (HOLD) at $48.06 (24.7x Forward P/E, 25.0% operating margin), whereas BMI carries 46.0/100 (HOLD) at $160.76 (31.0x Forward P/E, 18.8% operating margin). Technical & Structure Timing Caution: CGNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.9); meanwhile BMI trades in a Markup technical trend (SURGE options phase, RSI 62.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGNX leads the Growth & Scale pillar: CGNX posts +13.2% YoY revenue growth and +400.0% YoY earnings growth on $1.13B TTM revenue (69.7% gross margin, 25.0% operating margin), compared with BMI at +0.1% YoY revenue growth and +4.2% YoY earnings growth on $881M TTM revenue (41.6% gross margin, 18.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGNX cumulative revenue shifted +22.2% while BMI shifted +114.0%. In operating R&D and SG&A reinvestment, CGNX deploys 44.7% of Rev ($503M) (0 90-day corporate R&D disclosures) versus 22.8% of Rev ($201M) (0 disclosures) for BMI.

CGNX screens cheaper on headline valuation multiples. CGNX trades at 24.7x Forward P/E, 35.5x Trailing P/E, 2.71x PEG, and 7.0x EV/Revenue (25.4% FCF margin), whereas BMI trades at 31.0x Forward P/E, 35.5x Trailing P/E, 3.68x PEG, and 5.1x EV/Revenue (16.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGNX (15.1% ROE) versus BMI (18.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CGNX carries 53.5% implied volatility (16th %ile, Compressed (<25th %ile)), a 1.96x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.19β · 65% Vol realized risk). By comparison, BMI carries 39.0% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.49β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.